Cuproptosis-related gene expression is associated with immune infiltration and CD47/CD24 expression in glioblastoma, and a risk score based on these genes can predict the survival and prognosis of patients

Introduction Glioblastoma (GBM) is the most invasive type of glioma, is insensitive to radiotherapy and chemotherapy, and has high proliferation and invasive ability, with a 5-year survival rate of <5%. Cuproptosis-related genes (CRGs) have been successfully used to predict the prognosis of many types of tumors. However, the relationship between cuproptosis and GBM remains unclear. Methods Here, we sought to identify CRGs in GBM and elucidate their role in the tumor immune microenvironment and prognosis. To that aim, changes in CRGs in The Cancer Genome Atlas (TCGA) transcriptional and Gene Expression Omnibus (GEO) datasets (GEO4290 and GEO15824) were characterized, and the expression patterns of these genes were analyzed. Results A risk score based on CRG expression characteristics could predict the survival and prognosis of patients with GBM and was significantly associated with immune infiltration levels and the expression of CD47 and CD24, which are immune checkpoints of the “don't eat me “signal. Furthermore, we found that the CDKN2A gene may predict GBM sensitivity and resistance to drugs. Discussion Our findings suggest that CRGs play a crucial role in GBM outcomes and provide new insights into CRG-related target drugs/molecules for cancer prevention and treatment.

[1]  Hongtuan Zhang,et al.  Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma , 2022, Frontiers in Genetics.

[2]  Zhen Zhang,et al.  Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma , 2022, Frontiers in Immunology.

[3]  Hong Wang,et al.  A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma , 2022, Journal of oncology.

[4]  Wei Gao,et al.  Molecular Subtyping Based on Cuproptosis-Related Genes and Characterization of Tumor Microenvironment Infiltration in Kidney Renal Clear Cell Carcinoma , 2022, Frontiers in Oncology.

[5]  Xianwei Zhang,et al.  A novel Cuproptosis-related LncRNA signature to predict prognosis in hepatocellular carcinoma , 2022, Scientific Reports.

[6]  Jinhua Xu,et al.  Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma , 2022, Frontiers in Pharmacology.

[7]  P. Cobine,et al.  Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death. , 2022, Molecular cell.

[8]  G. Kroemer,et al.  Cuproptosis: a copper-triggered modality of mitochondrial cell death , 2022, Cell Research.

[9]  T. Golub,et al.  Copper induces cell death by targeting lipoylated TCA cycle proteins , 2022, Science.

[10]  Danhua Li,et al.  Relationship between hepatocellular carcinoma and depression via online database analysis , 2021, Bioengineered.

[11]  Y. Ye,et al.  Immunomodulation Induced During Interferon-α Therapy Impairs the Anti-HBV Immune Response Through CD24+CD38hi B Cells , 2020, Frontiers in Immunology.

[12]  Nadezhda T. Doncheva,et al.  The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets , 2020, Nucleic Acids Res..

[13]  Jian Shen,et al.  Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas , 2020, Frontiers in Immunology.

[14]  Qin Xu,et al.  Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery , 2020, Journal for ImmunoTherapy of Cancer.

[15]  G. Getz,et al.  Predicting and affecting response to cancer therapy based on pathway-level biomarkers , 2020, Nature Communications.

[16]  Voichita D. Marinescu,et al.  Whole-genome sequencing of glioblastoma reveals enrichment of non-coding constraint mutations in known and novel genes , 2020, Genome Biology.

[17]  Y. Ohe,et al.  CD20+ tumor‐infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma , 2020, Cancer science.

[18]  Aaron J. Johnson,et al.  Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity , 2020, Nature Communications.

[19]  F. Cheng,et al.  Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner , 2020, bioRxiv.

[20]  Guihua Tang,et al.  Development of an Immune Infiltration-Related Prognostic Scoring System Based on the Genomic Landscape Analysis of Glioblastoma Multiforme , 2020, Frontiers in Oncology.

[21]  Wange Lu,et al.  A HOTAIR regulatory element modulates glioma cell sensitivity to temozolomide through long-range regulation of multiple target genes , 2020, Genome research.

[22]  Xifeng Wu,et al.  Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients , 2019, Journal of Immunotherapy for Cancer.

[23]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[24]  C. Conrad,et al.  Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics , 2019, bioRxiv.

[25]  Y. Ouyang,et al.  Immune infiltration in renal cell carcinoma , 2019, Cancer science.

[26]  P. Spellman,et al.  Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets , 2019, Cancer cell.

[27]  C. James,et al.  Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth , 2019, Clinical Cancer Research.

[28]  D. Nam,et al.  TP53 gain-of-function mutation promotes inflammation in glioblastoma , 2019, Cell Death & Differentiation.

[29]  Stéphane Lehéricy,et al.  Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy. , 2019, Neuro-oncology.

[30]  A. Iwama,et al.  PLZF limits enhancer activity during hematopoietic progenitor aging , 2018, bioRxiv.

[31]  T. Cloughesy,et al.  Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation , 2018, Clinical Cancer Research.

[32]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[33]  Han-dong Wang,et al.  Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca2+-dependent pathway , 2018, Drug design, development and therapy.

[34]  B. Stockwell,et al.  Increased erythrophagocytosis induces ferroptosis in red pulp macrophages in a mouse model of transfusion. , 2018, Blood.

[35]  S. Lipton,et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018 , 2018, Cell Death & Differentiation.

[36]  M. Hegi,et al.  Glioma epigenetics: From subclassification to novel treatment options. , 2017, Seminars in cancer biology.

[37]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[38]  Sabine Borwege,et al.  PNIPAAm-co-Jeffamine® (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells. , 2017, Biomaterials.

[39]  Mary Goldman,et al.  Toil enables reproducible, open source, big biomedical data analyses , 2017, Nature Biotechnology.

[40]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[41]  P. Agostinis,et al.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation , 2016, Cell Death and Differentiation.

[42]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[43]  A. Brodbelt,et al.  Glioblastoma in England: 2007-2011. , 2015, European journal of cancer.

[44]  Sridhar Ramaswamy,et al.  Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..

[45]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[46]  Stephan Frank,et al.  MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma. , 2011, Cancer research.

[47]  F. Ali-Osman,et al.  A novel splice variant of GLI1 that promotes glioblastoma cell migration and invasion. , 2009, Cancer research.

[48]  Jayant P. Menon,et al.  Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. , 2006, Cancer cell.

[49]  Ricardo J. Flores,et al.  A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG , 2017, Cancer.

[50]  Jun S. Liu,et al.  TIMER : AWeb Server for Comprehensive Analysis of Tumor-In fi ltrating Immune Cells , 2017 .

[51]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.